Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data
et al., medRxiv, doi:10.1101/2020.11.29.20235218 (Preprint) (meta analysis)
6th independent analysis showing efficacy from the Boulware PEP trial. This prospective analysis corrects an error in the NEJM paper where shipping delays are omitted (still not corrected).42% reduction in COVID-19 (9.6% vs. 16.5%), RR 0.58 [0.35 - 0.97], p=0.044, for the original trial 3 day specification.Currently there are 8 HCQ post-exposure prophylaxis studies and meta analysis shows:
| Outcome | Improvement |
|---|---|
| Mortality | 46% lower [-80‑84%] |
| Hospitalization | 16% lower [-69‑58%] |
| Cases | 25% fewer [-1‑45%] |
|
risk of case, 42.0% lower, RR 0.58, p = 0.04, <= 3 days after exposure.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Wiseman et al., 2 Dec 2020, preprint, 4 authors.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.